The global market for neurodegeneration treatments is estimated to be 20 billion and will grow 6% annually. The most prevalent neurodegenerations are Alzheimer's disease ((AD)) and Parkinson's disease ((PD)). Nilotinib, a tyrosine kinase inhibitor developed by Novartis (NVS) and approved for leukemia treatment as Tasigna, is being tested in a phase-2 trial for treating AD. It is also being tested in two phase-2 trials for PD and a phase-1 trial for Huntington's disease. Although, no biotech investment is a sure bet, knowing a candidate drug's mechanism of action and its potential for treatment efficacy can